TKM-Ebola

TKM-Ebola is an experimental drug for the treatment of the Ebola virus disease. It is developed by Tekmira Pharmaceuticals, a Canadian pharmaceutical company. The drug is a small interfering RNA (siRNA) treatment designed to inhibit the replication of the Ebola virus.

History[edit | edit source]

TKM-Ebola was first developed in the early 2010s. In 2014, the drug was fast-tracked by the Food and Drug Administration (FDA) for use in humans following a successful trial in primates. However, the FDA placed a clinical hold on the drug in July 2014 due to safety concerns. The hold was partially lifted in August 2014, allowing the drug to be used in emergency cases.

Mechanism of Action[edit | edit source]

TKM-Ebola works by using siRNA to inhibit the replication of the Ebola virus. The siRNA is encapsulated in lipid nanoparticles to protect it from degradation and to enhance its delivery to target cells. Once inside the cell, the siRNA binds to the Ebola virus RNA and triggers its degradation, preventing the virus from replicating.

Clinical Trials[edit | edit source]

Several clinical trials have been conducted to test the safety and efficacy of TKM-Ebola. In a Phase I trial, the drug was found to be safe and well-tolerated. However, a Phase II trial was put on hold due to safety concerns. The drug has also been used on a compassionate use basis in patients with Ebola virus disease.

See Also[edit | edit source]

TKM-Ebola Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.